Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 11,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Chronic Hepatitis B
Interventions: Telbivudine (LdT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 1,869 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • Pasadena, California + 15 more

Conditions: Stroke
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
Interventions: CAL-101; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Chronic Disease
Interventions: Computer-Tailored Intervention, Motivational Interviewing, Motivational Enhancement Therapy; Behavioral
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 55 Years and older
Enrollment: 484 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: vorinostat; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia
Interventions: Allogeneic Cell Therapy w/ Tumor-derived Lypho; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia
Interventions: imatinib mesylate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 24
States / cities: Aurora, Colorado • Newark, Delaware • Fort Myers, Florida + 21 more

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Chronic Lymphocytic Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions: fludarabine phosphate, methoxyamine, laboratory biomarker analysis, pharmacological study, western blotting, mass spectrometry, DNA analysis; Drug · Other · Genetic
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: End-Stage Renal Disease
Interventions: angioplasty, surgery; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions: Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System; Drug · Device
Lead sponsor: Everett Meyer; Other
Eligibility: Up to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Participants, Chronic Diseases in Older Adults, Chronic Disease Prevention
Interventions: Walk Your Heart to Health; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Chronic Disease, Medication Adherence
Interventions: Standard off-the-shelf pillbox, Custom off-the-shelf pillbox, Custom designed and manufactured pillbox, Education & Training, Reflection on medication routines; Device · Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Back Pain, Lower Back Pain, Cervical Pain
Interventions: Naltrexone and Clonidine Combination, placebo; Drug
Lead sponsor: Annette C. Toledano MD; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Hand Eczema
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Phoenix, Arizona • Fountain Valley, California • Huntington Beach, California + 18 more

Conditions: Tinnitus
Interventions: Acoustic paradigms; Other
Lead sponsor: University of Regensburg; Other
Eligibility: 18 Years to 70 Years
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Champaign, Illinois • Austin, Texas

Conditions: COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
Interventions: MoblO2 controls O2 flow, MoblO2 does not control flow; Other
Lead sponsor: Minnesota HealthSolutions; Industry
Eligibility: 25 Years to 95 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Leukemia
Interventions: nilotinib, cytogenetic analysis, mutation analysis, polymerase chain reaction, pharmacological study; Drug · Genetic · Other
Lead sponsor: Cancer Trials Ireland; Network
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions: Cromolyn Sodium, Cetirizine Hydrochloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 80 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions: Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 40
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Tarzana, California • Torrance, California + 4 more

Conditions: Migraine Disorders
Interventions: Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more

Conditions: AML, ALL, Blast Crisis, MDS, Multiple Myeloma
Interventions: TG02 citrate, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Tragara Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 9
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Chronic Insomnia
Interventions: placebo, Zolpidem CR, Eszopiclone; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

Tactile Learning in Stroke Patients

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Sharing and Talking About my Preferences

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation

STI571 in Treating Patients With Recurrent Leukemia

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Prevention and Treatment of Hemodialysis Vascular Access Malfunction

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Church Implementation of a Social Support Intervention to Increase Physical Activity in Older African American Adults

Impact of Pillboxes on Medical Adherence

Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis

MoblO2 to Maintain Oxygenation

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Safety and Efficacy of Chronic Hypnotic Use 2